Signs Agreement with National Cancer Institute for the Development of Antibodies to Treat Prostate Cancer

Signs Collaborative Research Agreement with Ludwig Institute for Cancer Research to aid in validation of antibody targets being pursued for human diseases

December

Initiates MORAb-009 Randomized, Controlled Phase II Study in 1^st Line Pancreatic Cancer

October

Morphotek Receives Funding from the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies against Biowarfare Agents

September

Morphotek Receives Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies against Biowarfare Agents

May

Morphotek Signs Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma

April

Acquired by Eisai Corp.

February

Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers

October

June

February

Raised $40 Million to Advance its Antibody Pipeline

Initiation of Phase II Clinical Trial for MORAb-003 in Ovarian Cancer

FDA Accepts IND Application for MORAb-009

December

Exclusive License Agreement Signed with the National Cancer Institute
(MORAb-009)

September

Invitrogen Corporation Acquires Cell Line Optimization Service Business

February

FDA Accepts IND Application for MORAb-003

January

Development Grant Awarded by NCI

December

Exclusive License Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-004)

November

Morphotek Named “2004 Technology Company of the Year”

September

CRADA Signed with USAMRIID

July

Cross License Agreement Signed with Protein Design Labs

February

Series C Funding Raises $26 MM

October

Manufacturing Agreement Signed with Baxter Healthcare

September

PA Governor Mark Schweiker Awards Pennsylvania Opportunity Grant to Morphotek

July

Morphotek Awarded US Army Grant

May

Morphotek Expands Operations and Relocates to 41,000 sq ft Facility in Exton, PA

April

Research Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-003)

February

Research Agreement Signed with the Wistar Institute

August

Series B Funding Round Raises $10MM

November

Company’s Scientific Advisory Board Established

July

Company’s Board of Directors Established

May

Morphotek is Founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass